An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Lysosomes are subcellular organelles that are present in most cells, with the major exception of red blood cells.
The first evidence for a shockless treatment for atrial fibrillation (AF) will be presented today at Frontiers in CardioVascular Biology (FCVB) 2014 in Barcelona, Spain. T
The QT interval is part of the heart's electrical cycle as measured by ECG, and represents the electrical depolarization and repolarization of the ventricles. Lengthened intervals indicate dysfunction in the heart beat and are liable to lead to a five-fold increase in the risk of sudden death from heart failure.
Use of catheter ablation is not only beneficial for treating atrial flutter but also can significantly reduce hospital visits - both inpatient and emergency - and lower the risk for atrial fibrillation, according to research by UC San Francisco.
Administering low doses of a thyroid hormone to rats with diabetes helps restore hormone levels in their hearts and prevented deterioration of heart function and pathology, according to a new study by NYIT College of Osteopathic Medicine Professor and Biomedical Sciences Chair A. Martin Gerdes.
As the number of pacemakers implanted each year reaches into the millions worldwide, improving the lifespan of pacemaker batteries has been of great concern for developers and manufacturers.
iRhythm Technologies, Inc., a healthcare information services company, today announced that it closed a $17 million Series E financing led by Novo A/S, a global life science investment firm.
Researchers at the Cedars-Sinai Heart Institute have identified a heart-specific form of a protein, BIN1, responsible for sculpting tiny folds in pockets that are present on the surface of heart muscle cells.
Vivek Reddy, MD, Director of Arrhythmia Services for The Mount Sinai Hospital, reported his promising12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Dr. Reddy presented the one-year LEADLESS study data findings during his late-breaking clinical trial presentation on May 9 at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco, CA.
Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, is proud to announce the results of its trial on the Freedom Solo for approval on the US market presented at the 94th Annual Meeting of American Association for Thoracic Surgery in Toronto, Canada.
New research has found that bariatric surgery is an effective way to control weight in morbidly obese patients who are at risk for developing atrial fibrillation (AF).
Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it received U.S. Food and Drug Administration approval for the Mitroflow Aortic Pericardial Heart Valve with PRT.
Improved physician education and patient counseling about methadone safety and ECG monitoring to identify patients at high risk for cardiac problems will lead to safer use of the medication, according to the American Pain Society's Clinical Practice Guideline on Methadone Safety, published this week in The Journal of Pain.
GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
Initial blood pressure measurements in patients with diabetes should be taken from both arms, say researchers.
The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in patients with certain congenital heart defects, according to research presented by a U-M pediatric interventional cardiologist at the American College of Cardiology's 63rd Annual Scientific Session Sunday.
Daiichi Sankyo Company, Limited today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm).
Dramatic spikes in cases of Takotsubo cardiomyopathy, also called broken heart syndrome, were found in two states after major natural disasters, suggesting the stress of disasters as a likely trigger, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.
ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia.
Although genome-wide association studies have linked DNA variants in the gene SCN10A with increased risk for cardiac arrhythmia, efforts to determine the gene's direct influence on the heart's electrical activity have been unproductive. Now, scientists from the University of Chicago have discovered that these SCN10A variants regulate the function of a different gene, SCN5A, which appears to be the primary gene responsible for cardiac arrhythmia risk.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.